Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: Randomized, placebo-controlled, phase III study

Journal of Sexual Medicine

Volumn 10, Issue 9, 2013, Pages 2312-2325

  Mcmahon, Chris G ^a   Giuliano, Francois ^b   Dean, John ^c   Hellstrom, Wayne J G ^d   Bull, Scott ^e   Tesfaye, Fisseha ^e   Sharma, Om ^e   Rivas, David A ^e   Aquilina, Joseph W ^e  

^a Australian Centre for Sexual Health   (Australia)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c London Clinic Cancer Centre   (United Kingdom)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Concomitant Treatment; Dapoxetine; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitor; Premature Ejaculation

Indexed keywords

DAPOXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION OF CHANGE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; INTRAVAGINAL EJACULATORY LATENCY TIME; KIDNEY CYST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE OBSTRUCTION; PENIS DISEASE; PHASE 3 CLINICAL TRIAL; POSITIONAL DIZZINESS; PREMATURE EJACULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEXUAL INTERCOURSE; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL SYSTEM PARAMETERS; VERTIGO;

CONCOMITANT TREATMENT; DAPOXETINE; ERECTILE DYSFUNCTION; PHOSPHODIESTERASE TYPE 5 INHIBITOR; PREMATURE EJACULATION;

ADULT; AGED; BENZYLAMINES; COITUS; DOUBLE-BLIND METHOD; EJACULATION; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PREMATURE EJACULATION; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883519307     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12236     Document Type: Article

References (39)

1. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, Rosen RC, Sadovsky R, Waldinger M, Becher E, Broderick GA, Buvat J, Goldstein I, El-Meliegy AI, Giuliano F, Hellstrom WJG, Incrocci L, Jannini EA, Park K, Parish S, Porst H, Rowland D, Segraves R, Sharlip I, Simonelli C, and Tan HM. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010;7:2947-2969.
2. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-814.
3. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, Adaikan PG, Becher E, Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJG, Incrocci L, Laan E, Meuleman E, Perelman MA, Rosen RC, Rowland DL, Segraves R. An evidence-based definition of lifelong premature ejaculation: Report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med 2008;5:1590-1606.
4. Shabsigh R. Diagnosing premature ejaculation: A review. J Sex Med 2006;3(suppl 4):318-323.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington: American Psychiatric Association; 2000.
6. Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: Results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009;55:957-967.
7. Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, Rivas D. Treatment benefit of dapoxetine for premature ejaculation: Results from a placebo-controlled phase III trial. BJU Int 2009;103:651-658.
8. McMahon C, Kim SW, Park NC, Chang C-P, Rivas D, Tesfaye F, Rothman M, Aquilina J, on behalf of the Dapoxetine 3003 Study Investigators. Treatment of premature ejaculation in the Asia-Pacific region: Results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010;7:256-268.
9. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJG, Shabsigh R, Miloslavsky M, Kell S, for the Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: An integrated analysis of two double-blind, randomised controlled trials. Lancet 2006;368:929-937.
10. Janssen Cilag, AB. Priligy (dapoxetine) [prescribing information]. Sollentuna (Sweden): Janssen Cilag AB, 2008.
11. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270:83-90.
12. Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, Broderick G, Burnett A, Buvat J, Dean J, Donatucci C, Eardley I, Fugl-Meyer KS, Goldstein I, Hackett G, Hatzichristou D, Hellstrom W, Incrocci L, Jackson G, Kadioglu A, Levine L, Lewis RW, Maggi M, McCabe M, McMahon CG, Montague D, Montorsi P, Mulhall J, Pfaus J, Porst H, Ralph D, Rosen R, Rowland D, Sadeghi-Nejad H, Shabsigh R, Stief C, Vardi Y, Wallen K, Wasserman M. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010;7:3572-3588.
13. Heruti R, Shochat T, Tekes-Manova D, Ashkenazi I, Justo D. Prevalence of erectile dysfunction among young adults: Results of a large-scale survey. J Sex Med 2004;1:284-291.
14. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(suppl 4):S6-11.
15. Park K, Hwang EC, Kim SO. Prevalence and medical management of erectile dysfunction in Asia. Asian J Androl 2010;13:543-549.
16. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL. Prevalence of erectile dysfunction: A systematic review of population-based studies. Int J Impot Res 2002;14:422-432.
17. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007;120:151-157.
18. Pfizer, Inc. Viagra (sildenafil citrate) [package insert]. New York (NY): Pfizer Inc, 2005.
19. Seftel AD. Erectile dysfunction in the elderly: Epidemiology, etiology and approaches to treatment. J Urol 2003;169:1999-2007.
20. Fugl-Meyer K, Fugl-Meyer AR. Sexual disabilities are not singularities. Int J Impot Res 2002;14:487-493.
21. Nicolosi A, Buvat J, Glasser DB, Hartmann U, Laumann EO, Gingell C. Sexual behaviour, sexual dysfunctions and related help seeking patterns in middle-aged and elderly Europeans: The global study of sexual attitudes and behaviors. World J Urol 2006;24:423-428.
22. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T, for the GSSAB Investigators' Group. Sexual problems among women and men aged 40-80 y: Prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.
23. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID; AUA Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004;172:290-294.
24. Asimakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med 2012;9:2404-2416.
25. McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review. BJU Int 2006;98:259-272.
26. Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 2003;61:197-200.
27. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res 2006;18:104-110.
28. Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: The central role of perceived control. J Sex Med 2007;4:780-788.
29. Shabsigh R, Patrick DL, Rowland DL, Bull SA, Tesfaye F, Rothman M. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: Results from phase III trials with dapoxetine. BJU Int 2008;102:824-828.
30. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and premature ejaculation: Appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med 2008;5:492-499.
31. Belli H, Aslaner D, Ural C, Vardar MK, Yesilyurt S, Gul ES. Escitalopram related erectile dysfunction and spontaneous ejaculation during micturition. West Indian Med J 2010;59:715-716.
32. Labbate LA, Grimes J, Hines A, Oleshansky MA, Arana GW. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 1998;24:3-12.
33. Lee KU, Lee YM, Nam JM, Lee HK, Kweon YS, Lee CT, Jun TY Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig 2010;7:55-59.
34. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194.
35. Liu Q, Anderson KM. On adaptive extensions of group sequential trials for clinical investigations. J Am Stat Assoc 2008;103:1621-1630.
36. Feige AM, Pinsky MR, Hellstrom WJ. Dapoxetine for premature ejaculation. Clin Pharmacol Ther 2011;89:125-128.
37. McCarty E, Dinsmore W. Dapoxetine: An evidence-based review of its effectiveness in treatment of premature ejaculation. Core Evid 2012;7:1-14.
38. McMahon C. Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol 2007;30:314-315.
39. Porst H, McMahon CG, Althof SE, Sharlip I, Bull S, Aquilina JW, Tesfaye F, Rivas DA. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: Integrated analyses of two phase 3 dapoxetine trials. J Sex Med 2010;7:2231-2242.